sitagliptin stada 100 mg tabletki powlekane
stada arzneimittel ag - sitagliptin hydrochloride monohydrate - tabletki powlekane - 100 mg
sitagliptin stada 50 mg tabletki powlekane
stada arzneimittel ag - sitagliptin hydrochloride monohydrate - tabletki powlekane - 50 mg
spiriva 18 mcg proszek do inhalacji w kapsułkach twardych
boehringer ingelheim international gmbh - tiotropium bromide monohydrate - proszek do inhalacji w kapsułkach twardych - 18 mcg
jamesi 50 mg + 850 mg tabletki powlekane
zentiva, k.s. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
jamesi 50 mg + 1000 mg tabletki powlekane
zentiva, k.s. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
metformax combi 50 mg + 1000 mg tabletki powlekane
teva pharmaceuticals polska sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
metformax combi 50 mg + 850 mg tabletki powlekane
teva pharmaceuticals polska sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
piperacillin + tazobactam eugia 4 g + 0,5 g proszek do sporządzania roztworu do infuzji
eugia pharma (malta) ltd. - piperacillin monohydrate + tazobactamum natricum - proszek do sporządzania roztworu do infuzji - 4 g + 0,5 g
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - leki stosowane w cukrzycy - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. potrójnej terapii skojarzonej), jako uzupełnienie diety i ćwiczeń fizycznych u pacjentów niedostatecznie kontrolowanych o ich maksymalnej tolerowanej dawki sulfonylomocznika z metforminą i. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.